About the recommendation of the GINA strategy report on asthma step 1.

There is not yet sufficient evidence to transfer the use of as-needed low dose ICS–formoterol, as GINA has recommended since 2019, instead of as-needed SABA to patients affected by step 1 asthmahttps://bit.ly/2G1IieN